| | Class 2 Device Recall V8 Serum Protein SPE Kit |  |
| Date Initiated by Firm | September 14, 2026 |
| Date Posted | November 17, 2026 |
| Recall Status1 |
Open3, Classified |
| Recall Number | Z-0469-2027 |
| Recall Event ID |
99987 |
| Product Classification |
Electrophoretic, protein fractionation - Product Code CEF
|
| Product | V8 Serum Protein SPE Kit, Cat. No.: 1805, containing V8 SPE Diluent, Product No.: 552512 |
| Code Information |
Catalog No. 1805, Kit Lot 4-26-1805, expiration date 2028-05-31, UDI-DI: M52518050.
Affected component Product No. 552512, Lot 3-26-552512 |
| FEI Number |
1618982
|
Recalling Firm/ Manufacturer |
Helena Laboratories, Corp.
1530 Lindbergh Dr
Beaumont
TX
77707-4131
|
| For Additional Information Contact | 409-842-3714 |
Manufacturer Reason for Recall | Assayed quality control (QC) material (both normal and abnormal control levels) run with kits manufactured using diluent lot 3-26-552512 (a component of finished kit lot 4-26-1805) shows a reproducible shift in serum protein electrophoretic fraction distribution relative to historical/comparator diluent lots: decreased albumin (approximately 6-10 relative percentage points, roughly -0.4 to -0.55 g/dL where total protein is known) and increased beta and gamma globulin fractions (approximately +1 to +3 relative percentage points, roughly +0.05 to +0.28 g/dL). This may result in QC failures or prompt unnecessary clinical workup for hypoalbuminemia or could mask a mild true elevation in albumin, while falsely elevated beta/gamma fractions could prompt unnecessary or premature follow-up testing for suspected gammopathy. |
FDA Determined Cause 2 | Component change control |
| Action | On 9/14/2026, recall notices were emailed to customers who were asked to do the following:
1) Discontinue use of any remaining kits. Examine your inventory and quarantine any remaining kits.
2. Review your quality control records associated with this lot.
3. If you have supplied kits from this lot to other laboratories or sites within your organization, forward this notification to them at once so they may take the same action.
4) Complete and return the response form to technicalservice@helena.com
Distributors are asked to forward the enclosed customer notification letter to each affected or potentially affected account. Advise customers to return the affected kits to you for credit and/or replacement.
If you have any questions, contact the firm at technicalservice@helena.com or 1-800-231-5663 extension 1600, Monday through Friday, 8:00 AM to 5:00 PM Central Time. |
| Quantity in Commerce | 121 |
| Distribution | Worldwide - US Nationwide distribution in the states of MI, CA, TN, MS, MO, TX, IN, FL and the countries of PRY, CAN, ISR, PHL, TTO.
|
| Total Product Life Cycle | TPLC Device Report |
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls. 2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall. 3 The manufacturer has initiated the recall and not all products have been corrected or removed. This record will be updated as the status changes.
|
|
|
|